ZymoGenetics Inc (ZGEN)
Q2 2010 Earnings Call
August 03, 2010 4:30 p.m. ET
Susan Specht – Director of Corporate Communications
Doug Williams – CEO
Jim Johnson – EVP, CFO, Secretary, Treasurer
Lenny Ramos – SVP, CMO
Stephen Zaruby – President
Brian Abrahams – Oppenheimer & Co.
Edward Tenthoff - Piper Jaffray
Jonathan Eckard – Leerink Swann & Company
John Sonnier - William Blair & Company
Nicholas Abbot - Barclays Capital
Chad Messer – Piper Jaffray
Paul Latta – McAdams Wright Ragen
Greetings, and welcome to the ZymoGenetics Second Quarter 2010 Financial Results Conference Call. At this time all participants are in a listen only mode. A brief question-and-answer will follow with formal presentation. (Operator Instructions.). As a reminder this conference is being recorded.
It is now my pleasure to introduce your host, Susan Specht, Director of Corporate Communications for ZymoGenetics. Thank you, Ms. Specht. You may now begin.
Good afternoon everyone, and welcome to our second quarter 2010 conference call. Before we begin, I would like to remind you that we will be making forward-looking statements as a part of our prepared remarks, and in answering your questions. These statements are subject to many risks and uncertainties that could cause actual outcomes to be much different than we predict. Please look at our SEC filings, including the Form 10-K, for more information.
And now I'll turn the call over to our CEO, Doug Williams.
Thanks, Susan. And good afternoon to everyone. Thank you for joining us today for our second quarter earnings call. We're very pleased with our performance during the quarter with continuing revenue growth in RECOTHROM, progress moving our development candidates forward towards important data events, and ongoing benefits in our cost structure due to last year's restructuring.